SB 1306 adds Section 11112 to the Health and Safety Code to carve out chemical mixtures that contain gamma-butyrolactone (GBL) at 70 percent or less by weight or volume from several state precursor-control provisions. The exemption covers mixtures obtained from in‑ or out‑of‑state sources and applies to sales, transfers, exports, and other furnishing of those mixtures within or across state lines.
The bill also narrows application of a separate bill-of-sale/recordkeeping provision when it would operate solely because GBL is present.
The legislation’s stated aim is to reduce compliance costs and regulatory friction for semiconductor fabrication and related industrial users that rely on GBL-containing solvents, bringing California into alignment with a 2010 DEA rule (21 C.F.R. §1310.12). At the same time, the bill removes several state-level reporting and permitting touchpoints that prosecutors and regulators currently use to detect diversion, creating practical questions about measurement, oversight, and who certifies mixture concentrations.
At a Glance
What It Does
The bill exempts ‘‘chemical mixtures containing gamma‑butyrolactone’’ at concentrations of 70% or less from Sections 11100, 11100.1, 11103, and 11106 of the Health and Safety Code, and limits application of Section 11107 when triggered solely by GBL. It defines the covered mixtures and ‘‘inert carrier’’ and covers transactions with both in‑state and out‑of‑state parties, including exports.
Who It Affects
Primary targets are semiconductor fabs, industrial users of specialty solvents, and their upstream chemical suppliers and distributors; state DOJ and other regulators that administer precursor permitting, reporting, and enforcement; and compliance teams responsible for procurement and hazardous‑materials recordkeeping.
Why It Matters
The change eliminates a layer of California‑specific precursor controls that many manufacturers say duplicate federal rules, reducing permitting and reporting burdens but also removing statutory hooks that currently generate tips, loss reports, and records useful for diversion investigations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
California currently treats gamma‑butyrolactone (GBL) as a listed precursor chemical at any concentration, which triggers permitting, loss/theft reporting, and bill‑of‑sale requirements for entities that sell, transfer, or otherwise furnish it. SB 1306 creates a statutory exemption for mixtures that contain GBL at 70% or less by weight or volume and at least one other non‑trivial component.
The exemption covers receipt of such mixtures from suppliers inside or outside California and their sale, transfer, or export to parties both inside and outside the state.
The bill borrows the 70% concentration benchmark the DEA used in a 2010 federal rule that exempted certain GBL mixtures from provisions of the federal Controlled Substances Act. SB 1306 codifies that threshold into state law, and it adds short statutory definitions for ‘‘chemical mixtures containing gamma‑butyrolactone’’ and ‘‘inert carrier,’’ the latter meant to carve out common delivery solvents or diluents that do not change how GBL functions in a process.Operationally, the exemption removes requirements that have driven state permitting applications and routine reporting when GBL was present at any level.
That will simplify procurement and logistics for fabs and chemical distributors but also eliminates some mandatory reporting streams and permit records that state investigators currently use to detect diversion or theft. The bill leaves intact prohibitions and controls on pure GBL or mixtures above 70%, so the statutory restriction remains for high‑concentration material.Practical compliance questions follow immediately: how parties must demonstrate a mixture’s concentration, who bears the burden to test or certify it, how ‘‘inert carrier’’ will be interpreted when suppliers reformulate, and what substitute recordkeeping (if any) will preserve information currently captured under Sections 11100–11107.
The bill contains no new testing protocol, labeling mandate, or certification regime, so affected firms and regulators will need to bridge those gaps through guidance or transaction practices.
The Five Things You Need to Know
The bill exempts mixtures containing GBL at 70% or less (by weight or volume) from Sections 11100, 11100.1, 11103, and 11106 of the Health and Safety Code.
It narrows Section 11107’s bill‑of‑sale and $100 reporting requirements only when those requirements would apply solely because GBL is present in a mixture.
The exemption applies to mixtures ‘‘obtained or received’’ from sources inside or outside California and to mixtures ‘‘sold, transferred, exported, or otherwise furnished’’ to recipients inside or outside the state.
The statutory definition requires mixtures to include at least one other component that is not ‘‘solely an inert carrier or an impurity,’’ and separately defines ‘‘inert carrier’’ as a delivery aid that does not interfere with GBL’s function.
The bill’s legislative findings cite the DEA’s 2010 regulatory exemption (21 C.F.R. §1310.12) and emphasize semiconductor manufacturing as the principal policy rationale for the change.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Why the Legislature says this change is needed
This part lays out the policy case: California’s semiconductor ecosystem depends on specialty solvents like GBL; the DEA adopted a 70% exemption in 2010; and state law remains more restrictive, imposing permitting and reporting burdens that the sponsor says are unnecessary for in‑industry uses. The findings also compare other states’ approaches (Florida, New Jersey, Arizona, Texas) to argue that California’s current rules put the state at a competitive disadvantage for advanced manufacturing.
Which state precursor provisions are carved out
Subsection (a) explicitly removes the named precursor‑control sections (11100, 11100.1, 11103, 11106) from applying to covered GBL mixtures. Practically, that means manufacturers, wholesalers, retailers, and other sellers of qualifying mixtures do not need the state permits or to follow the reporting and transfer controls those sections impose when the only issue is the presence of GBL at ≤70%.
When the $100 reagent/sales record rule stops applying
Subsection (b) limits Section 11107’s reach for the defined mixtures if the only reason Section 11107 would apply is the presence of GBL. Because Section 11107 requires bills of sale and retention of transaction records for certain reagents above $100, this provision removes that obligation for otherwise qualifying mixtures, leaving other triggers for recordkeeping intact.
How the bill defines covered mixtures and inert carriers
Subsection (c) supplies two key definitions. ‘‘Chemical mixtures containing gamma‑butyrolactone’’ requires GBL at ≤70% and at least one other non‑trivial component, excluding mere impurities or pure inert carriers. ‘‘Inert carrier’’ is defined narrowly as a delivery aid that does not change GBL’s function. Those textual choices set up future disputes over testing methods, reformulation practices, and whether a compound is ‘‘solely’’ an inert carrier.
This bill is one of many.
Codify tracks hundreds of bills on Justice across all five countries.
Explore Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Semiconductor fabrication facilities and chemical end‑users — The change removes state permit and reporting obligations for many solvents they buy, simplifying procurement, lowering administrative costs, and shortening lead times for critical supplies.
- Chemical manufacturers and distributors — Suppliers of formulated GBL blends can ship into and out of California without triggering state precursor permits or loss/theft reporting tied solely to GBL’s presence, reducing transaction friction and compliance overhead.
- Out‑of‑state suppliers and exporters — The statutory language expressly covers materials ‘‘obtained or received’’ from outside California and permits exports, making interstate and international shipments administratively simpler for vendors and logistics providers.
- Procurement and compliance teams at advanced‑manufacturing firms — Fewer state filings and permit renewals mean smaller compliance programs for this specific input, allowing teams to focus resources on other regulatory obligations.
Who Bears the Cost
- State DOJ investigators and local law enforcement — Removing mandatory permits and loss/theft reports reduces statutory reporting streams that often trigger diversion investigations, potentially making chemical tracking and theft detection harder.
- Public‑health and diversion‑prevention officials — Less granular state recordkeeping could limit epidemiologic or law‑enforcement data on precursor flows, constraining threat assessments and interagency coordination.
- Smaller laboratories and specialty users outside semiconductor supply chains — Those users may lose default protections if suppliers rely on the exemption and cease routine disclosures; they will need to demand alternative documentation to manage risk.
- Regulators and compliance teams tasked with guidance — The bill creates interpretive gaps (concentration testing, ‘‘inert carrier’’ determinations) that agencies must resolve without any new statutory testing or certification regime, likely producing administrative burden and legal challenges.
Key Issues
The Core Tension
The bill trades regulatory visibility and statute‑based reporting that help detect diversion for reduced compliance costs and operational friction for critical industries. That trade‑off pits the legitimate public‑safety goal of controlling precursors against the economic and supply‑chain goal of keeping advanced‑manufacturing inputs flowing smoothly—without providing a clear mechanism to preserve oversight while eliminating burdens.
The bill simplifies compliance by removing specific statutory hooks, but it does not create a parallel certification, testing, labeling, or recordkeeping regime to replace them. That omission transfers the burden of proving compliance—i.e., that a mixture is at or below 70% and contains a non‑inert co‑component—onto private parties, purchasers, or future agency guidance.
Expect disputes between buyers and sellers about who pays for concentration testing, what sampling methodology governs, and what proof satisfies a regulator or a criminal investigator.
The statutory definitions attempt precision but introduce litigation risk. The phrase ‘‘not solely an inert carrier or an impurity’’ invites factual fights over formulations that intentionally skirt the line between a functional diluent and an ‘‘inert carrier.’’ Similarly, the bill’s reliance on a percent‑by‑weight‑or‑volume metric without prescribing measurement protocols leaves open whether manufacturers can rely on formulation records, supplier certificates, or must perform independent assays.
Finally, removing state reporting and permit triggers will likely reduce low‑cost signals (like routine bill‑of‑sale retention and theft notifications) that currently surface diversion; absent new voluntary industry standards or DOJ guidance, enforcement agencies will need to develop alternative intelligence sources.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.